European Patent Office Upholds Angiotech's Patent For Drug-Coated Stents

Law360, New York (January 24, 2005, 12:00 AM EST) -- The European Patent Office has upheld the validity of Canadian medical device maker Angiotech Pharmaceuticals’ patent on specially coated medical stents, the company said Monday.

The EPO maintained the validity of Angiotech's patent with various claims, including claims to stents coated with paclitaxel and a polymeric carrier.

“This decision reaffirms Angiotech's continued patent protection in Europe,” the company said in a statement.

The patent is one of many in Angiotech's portfolio, including the Boston Scientific Taxus stent program. The stents, coated with paclitaxel and a polymeric...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.